INCR: רווח למניה בשנים עשר החודשים האחרונים InterCure Ltd

InterCure Ltd. (INCR) is positioned for growth due to its status as the undisputed favorite in the Israeli medical cannabis sector. This potential is based on expanding pharmacy coverage in Germany and Israel under strict GMP control. The TTM annual earnings per share confirms the trend, with the current level sitting around -1.00. Cost optimization through external logistics and outsourced marketing helps the company adapt flexibly to regulatory changes.

Conservative capital demands absolute transparency regarding the business's actual earnings per share. This indicator aggregates net income over a rolling year, excluding short-term fluctuations to assess margin sustainability. For InterCure Ltd. (INCR), this is critical, as regulatory compliance costs limit the effects of production scaling. The investor sees the real efficiency of capital net of operating expenses. The current trailing 12-month EPS value objectifies this trend.